PATENT COOPERATION TREATY

Γo:		CHING AUTHO				PCT	
see form PCT/ISA/220					WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY		
			•			(PCT Rule 43bis.1)	
					Date of mailing (day/month/year)	see form PCT/ISA/210 (second	sheet)
Applicant's or agent's file reference see form PCT/ISA/220					FOR FURTHER ACTION See paragraph 2 below		
	national application N NB2006/000876	lo.	International filli	ng date (c	lay/month/year)	Priority date (day/monthly 17.03.2005	ear)
Inter	national Patent Class . C07D405/06 C0	sification (IPC) or 07D405/14 C0	I both national clas 7D211/34 C07	sification D471/04	and IPC 4 C07D401/04	A61K31/454 A61P31/18	
	icant ZER, INC.						
1.	This opinion co	ntains indicati	ons relating to	the foll	owing items:		
••	_						
	⊠ Box No. I	Basis of the or	DILION				
	☐ Box No. II	Priority		بممد طفني	and to novelty in	ventive sten and industrial ap	plicability
	Box No. III			with rega	are to noveity, in	ventive step and industrial ap	p,
	☐ Box No. IV	Lack of unity of	of invention				or industrial
	⊠ Box No. V	applicability; c	itations and exp	olanation	s.1(a)(i) with rega s supporting suc	ard to novelty, inventive step on the statement	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
	☐ Box No. VI	Certain docum			-1!4!		
	Box No. VII		s in the internat				
	🛛 Box No. VIII	Certain obser	vations on the i	nternatio	nal application		-
2.	FURTHER ACT		•				
	written opinion on the applicant charmational Bu will not be so co	of the Internation ooses an Autho reau under Rule Insidered.	nal Preliminary rity other than t e 66.1 <i>bis</i> (b) tha	Examinin his one to t written o	o be the IPEA ar	on will usually be considered to EA") except that this does not not the chosen IPEA has notife international Searching Author	od the rity
		EA a written rep mailing of Forn	in together win	ara annr	ooriate with altie	of the IPEA, the applicant is in endments, before the expiration 22 months from the priority of	,,, 0, 0 ,,,,,,,
	For further optic	ons, see Form F	CT/ISA/220.				
3.	For further deta	ils, see notes to	Form PCT/ISA	<i>[</i> 220.			
Na	me and mailing addre	ess of the ISA:		Date of this opin	completion of	Authorized Officer	Solketes Polonio,
_	Europear	n Patent Office - F HV Rijswijk - Pay	P.B. 5818 Patentla	1 '		Diederen, J	

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/IB2006/000876

	Во	x No	p. I Basis of the opinion
1.	Wii	gard to the language, this opinion has been established on the basis of:	
	\boxtimes	the	e international application in the language in which it was filed
		a t pu	ranslation of the international application into , which is the language of a translation furnished for the rposes of international search (Rules 12.3(a) and 23.1 (b)).
2.	Wi ne	th re	gard to any nucleotide and/or amino acid sequence disclosed in the international application and early to the claimed invention, this opinion has been established on the basis of:
	а.	type	of material:
			a sequence listing
			table(s) related to the sequence listing
	nat of material:		
			on paper
			in electronic form
	C.	time	of filing/furnishing:
			contained in the international application as filed.
			filed together with the international application in electronic form.
			furnished subsequently to this Authority for the purposes of search.
3	. 🗆	h: Cc	addition, in the case that more than one version or copy of a sequence listing and/or table relating thereto as been filed or furnished, the required statements that the information in the subsequent or additional opies is identical to that in the application as filed or does not go beyond the application as filed, as opropriate, were furnished.
4	۸.		anal comments:

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/IB2006/000876

Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability						
The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non obvious), or to be industrially applicable have not been examined in respect of						
		the entire international application				
	\boxtimes	claims Nos. 11-14				
because:						
	⊠	the said international application, or the said claims Nos. 11-14 (with respect to industrial application) relate to the following subject matter which does not require an international search (specify):				
		see separate sheet				
		the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify):				
		the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed (specify):				
		no international search report has been established for the whole application or for said claims Nos.				
		a meaningful opinion could not be formed without the sequence listing; the applicant did not, within the prescribed time limit:				
		☐ furnish a sequence listing on paper complying with the standard provided for in Annex C of the Administrative Instructions, and such listing was not available to the International Searching Authority in a form and manner acceptable to it.				
		furnish a sequence listing in electronic form complying with the standard provided for in Annex C of the Administrative Instructions, and such listing was not available to the International Searching Authority in a form and manner acceptable to it.				
		pay the required late furnishing fee for the furnishing of a sequence listing in response to an invitation under Rules 13 ter. 1(a) or (b).				
		a meaningful opinion could not be formed without the tables related to the sequence listings; the applicant did not, within the prescribed time limit, furnish such tables in electronic form complying with the technical requirements provided for in Annex C-bis of the Administrative Instructions, and such tables were not available to the International Searching Authority in a form and manner acceptable to it.				
		the tables related to the nucleotide and/or amino acid sequence listing, if in electronic form only, do not comply with the technical requirements provided for in Annex C-bis of the Administrative Instructions.				
		See Supplemental Box for further details				

Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

1,2,4,5,7-15

No: Claims

3,6

Inventive step (IS)

Yes: Claims

1,2,4,5,7-15

No: 0

Claims

3,6

Industrial applicability (IA)

Yes: Claims

1-10,15

No: Claims

2. Citations and explanations

see separate sheet

Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

Claims 11-14 relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(I) PCT).

Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Reference is made to the following document:

D1: WO 90/05133 A (PFIZER LIMITED; PFIZER INC) 17 May 1990 (1990-05-17)

D2: WO 03/030898 A (MERCK & CO., INC; KIM, RONALD, M; CHANG, JIANG;

CHAPMAN, KEVIN, T; MIL) 17 April 2003 (2003-04-17)

Document D1 discloses in examples 1-13 and 23 compounds which are novelty destroying for claim 6 of the present application. Examples 14-21 show examples which are novelty destroying for claim 3. Claims 3 and 6 are therefore not novel with respect to Article 33(2) PCT and can therefore also not be considered inventive according to Article 33(3) PCT.

Document D2 discloses piperidine comprising compounds for use in the treatment of HIV. This disclosure is considered to represent the closest prior art. The difference of the compounds of document D2 is enormous. The problem to be solved by the applicant was to provide alternative compounds for the treatment of HIV. Starting from document D2, a skilled person would not come to the solution of the present application as he would have to change the compounds of D2 completely. He would not have an incentive in the prior art to do so. It is therefore considered that the subject-matter of the present application, in as far it comprises novel subject-matter (claims 1,2,4,5,7-15), is inventive with respect to Article 33(3) PCT.

WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (SEPARATE SHEET)

International application No.

PCT/IB2006/000876

Re Item VIII

Certain observations on the international application

In the present set of claims, definitions for e.g. alkyl are given in the description which are not common to a person skilled in the art. Alkyl can mean a cyclic structure for example. This renders the scope of the entire application unclear for a person skilled in the art.

Claim 2 refers to an embodiment wherein a radical R3 is mentioned. There is however no definition given for said R3. This renders the scope of claim 2 unclear.